Used in targeted cancer therapy, particularly for B-cell malignancies such as non-Hodgkin’s lymphoma. It binds specifically to the CD79b protein on the surface of B-cells, enabling selective delivery of cytotoxic agents when conjugated to a drug. This targeted approach minimizes damage to healthy cells and enhances treatment efficacy. It serves as a reference standard in the development and validation of antibody-drug conjugates (ADCs), supporting research and quality control in biopharmaceutical manufacturing.